Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.39 |
| ▸ | EBP | Q15125 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | CCR3 | P51677 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL75693 | 1.00 | MCHR1 (0.44) | MCHR1LMNAPROKR1EBPSIGMAR1 | |
| SCHEMBL1420662 | 0.87 | MCHR1 (0.42) | MCHR1LMNAPROKR1EBPSIGMAR1 | |
| SCHEMBL1420663 | 0.87 | MCHR1 (0.42) | MCHR1LMNAPROKR1EBPSIGMAR1 | |
| SCHEMBL73203 | 0.87 | MCHR1 (0.43) | MCHR1LMNAPROKR1EBPSIGMAR1 | |
| SCHEMBL73202 | 0.87 | MCHR1 (0.43) | MCHR1LMNAPROKR1EBPSIGMAR1 | |
| SCHEMBL74213 | 0.87 | MCHR1 (0.45) | MCHR1LMNAPROKR1EBPSIGMAR1 | |
| SCHEMBL74214 | 0.87 | MCHR1 (0.45) | MCHR1LMNAPROKR1EBPSIGMAR1 | |
| SCHEMBL83172 | 0.86 | MCHR1 (0.44) | MCHR1LMNAPROKR1EBPSIGMAR1 | |
| SCHEMBL1463274 | 0.86 | MCHR1 (0.42) | MCHR1LMNAPROKR1EBPSIGMAR1 | |
| SCHEMBL1463315 | 0.86 | MCHR1 (0.42) | MCHR1LMNAPROKR1EBPSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045422-B2 | Piperidine derivatives with pesticidal properties | SYNGENTA PARTICIPATIONS AG (CH) | 2015-06-02 | — | — | US | disclosed |
| US-20130310399-A1 | CHEMICAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2013-11-21 | — | — | US | disclosed |
| US-8546569-B2 | Chemical compounds | SYNGENTA CROP PROTECTION, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| EP-1763302-B1 | CHEMICAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2013-03-06 | — | — | EP | disclosed |
| US-20120270885-A1 | CHEMICAL COMPOUNDS | SYNGENTA CROP PROTECTION LLC (US) | 2012-10-25 | — | — | US | disclosed |
| US-8129534-B2 | Chemical compounds | SYNGENTA CROP PROTECTION, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090042938-A1 | Chemical Compounds | SYNGENTA CROP PROTECTION, INC. (US) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270885-A1 | CHEMICAL COMPOUNDS | H1-0, CHRM1, MRM1 | MCHR1 455/4885LMNA 2045/4885PROKR1 2895/4885 |
| US-20090042938-A1 | Chemical Compounds | CHRM1, MRM1, H1-0 | MCHR1 439/4885LMNA 1783/4885PROKR1 2813/4885 |
| US-20130310399-A1 | CHEMICAL COMPOUNDS | ACHE, CHRM1, CHRM2 | MCHR1 391/4885LMNA 2632/4885PROKR1 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.